<div id=toc></div>

# Table of Contents

- [q-bio.QM](#q-bio.QM) [Total: 3]
- [q-bio.MN](#q-bio.MN) [Total: 1]
- [stat.ML](#stat.ML) [Total: 1]
- [cs.CV](#cs.CV) [Total: 1]
- [cs.AI](#cs.AI) [Total: 1]
- [stat.ME](#stat.ME) [Total: 1]
- [cs.LG](#cs.LG) [Total: 1]


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [1] [Deep Clustering for Blood Cell Classification and Quantification](https://arxiv.org/abs/2509.19399)
*Mihaela Macarie-Ancau,Adrian Groza*

Main category: q-bio.QM

TL;DR: 提出了一种两阶段深度聚类方法，用于从高维信号数据中分类血细胞，包括红细胞和血小板的分离以及红细胞亚型的进一步分类。


<details>
  <summary>Details</summary>
Motivation: 提高血液分析的自动化水平，为医学和兽医学应用开发低成本、自动化的血液分析系统。

Method: 第一阶段使用改进的自编码器和IDEC算法分离红细胞和血小板；第二阶段通过变分深度嵌入方法进一步分类红细胞亚型。

Result: 初步结果表明该方法在有限监督下能有效区分不同的血细胞群体。

Conclusion: 该方法在血液细胞分类方面显示出潜力，有助于开发适用于兽医和生物医学的低成本自动化血液分析系统。

Abstract: Accurate classification of blood cells plays a key role in improving
automated blood analysis for both medical and veterinary applications. This
work presents a two-stage deep clustering method for classifying blood cells
from high-dimensional signal data. In the first stage, red blood cells (RBCs)
and platelets (PLTs) are separated using a combination of an improved
autoencoder and the IDEC algorithm. The second stage further classifies RBC
subtypes, pure RBCs, reticulocytes, and clumped RBCs, through a variational
deep embedding (VaDE) approach. Due to the lack of detailed cell-level labels,
soft classification probabilities are generated from sample-level data to
approximate the true distributions. The aim is to contribute to the development
of low-cost, automated blood analysis systems suitable for veterinary and
biomedical use. Initial results indicate this method shows promise in
effectively distinguishing different blood cell populations, even with limited
supervision.

</details>


### [2] [Integrating Mechanistic Modeling and Machine Learning to Study CD4+/CD8+ CAR-T Cell Dynamics with Tumor Antigen Regulation](https://arxiv.org/abs/2509.19536)
*Saranya Varakunan,Melissa Stadt,Mohammad Kohandel*

Main category: q-bio.QM

TL;DR: 本文提出了一个扩展的数学模型来研究CAR-T细胞治疗中CD4和CD8亚群的作用，通过微分方程模拟细胞动态和相互作用，发现1:1的CD4:CD8比例能增强治疗效果。


<details>
  <summary>Details</summary>
Motivation: CAR-T细胞疗法在血液恶性肿瘤中显示出显著成功，但患者反应差异很大，且CD4和CD8亚群的作用尚未完全理解。需要定量框架来优化治疗和患者分层。

Method: 建立扩展的数学框架，通过微分方程明确模拟CD4辅助和CD8细胞毒性谱系及其与肿瘤抗原负荷的相互作用。整合前馈神经网络提高预测鲁棒性，并应用SHAP分析解释网络预测。

Result: 敏感性分析确定效应细胞增殖爆发大小、抗原周转和CD8扩增速率是治疗结果的主要决定因素。虚拟患者模拟显示1:1 CD4:CD8比例相对于仅CD8产品能增强CAR-T扩增和肿瘤清除。

Conclusion: 这项工作强调了CD4和CD8 CAR-T细胞的协同作用，为优化治疗和患者分层提供了定量基础。

Abstract: Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success
in hematological malignancies, yet patient responses remain highly variable and
the roles of CD4 and CD8 subsets are not fully understood. We present an
extended mathematical framework of CAR-T cell dynamics that explicitly models
CD4 helper and CD8 cytotoxic lineages and their interactions with tumor antigen
burden. Building on the Kirouac et al. (2023) model of antigen-regulated
memory, effector, and exhaustion transitions, our system of differential
equations incorporates cytokine-mediated modulation of CD8 proliferation,
cytotoxicity, and memory regeneration by CD4 T cells. Sensitivity analyses
identify effector proliferation burst size, antigen turnover, and CD8 expansion
rates as dominant determinants of treatment outcome. Virtual patient
simulations reproduce clinical findings that a 1:1 CD4:CD8 ratio enhances CAR-T
expansion and tumor clearance relative to CD8-only products. Finally, we
integrate a feed-forward neural network trained on noisy virtual patient data
to improve predictive robustness, and apply SHAP analysis to interpret the
network predictions and compare them with mechanistic sensitivity analyses.
This work highlights the synergistic roles of CD4 and CD8 CAR-T cells and
provides a quantitative foundation for optimizing treatments and patient
stratification.

</details>


### [3] [Dynamicasome: a molecular dynamics-guided and AI-driven pathogenicity prediction catalogue for all genetic mutations](https://arxiv.org/abs/2509.19766)
*Naeyma N Islam,Mathew A Coban,Jessica M Fuller,Caleb Weber,Rohit Chitale,Benjamin Jussila,Trisha J. Brock,Cui Tao,Thomas R Caulfield*

Main category: q-bio.QM

TL;DR: 该论文提出了一种结合分子动力学模拟和AI模型的方法，用于提高基因突变致病性预测的准确性。


<details>
  <summary>Details</summary>
Motivation: 当前基因组医学中许多突变的致病性未知，现有AI预测工具在验证数据集上准确性较低，这阻碍了其在诊断和临床决策中的应用。

Method: 对疾病基因PMM2进行全面的突变分析，对每个变体的结构模型进行分子动力学模拟，将详细的构象数据整合到基于AI的模型中。

Result: 基于该数据集训练的AI模型在预测已知突变致病性方面优于现有工具，最佳性能的神经网络模型还能预测目前被认为意义不明的PMM2突变的致病性。

Conclusion: 该方法有助于减轻基因组医学中未知变异的负担，提高致病性预测的准确性。

Abstract: Advances in genomic medicine accelerate the identi cation of mutations in
disease-associated genes, but the pathogenicity of many mutations remains
unknown, hindering their use in diagnostics and clinical decision-making.
Predictive AI models are generated to combat this issue, but current tools
display low accuracy when tested against functionally validated datasets. We
show that integrating detailed conformational data extracted from molecular
dynamics simulations (MDS) into advanced AI-based models increases their
predictive power. We carry out an exhaustive mutational analysis of the disease
gene PMM2 and subject structural models of each variant to MDS. AI models
trained on this dataset outperform existing tools when predicting the known
pathogenicity of mutations. Our best performing model, a neuronal networks
model, also predicts the pathogenicity of several PMM2 mutations currently
considered of unknown signi cance. We believe this model helps alleviate the
burden of unknown variants in genomic medicine.

</details>


<div id='q-bio.MN'></div>

# q-bio.MN [[Back]](#toc)

### [4] [Meta-analysis and Topological Perturbation in Interactomic Network for Anti-opioid Addiction Drug Repurposing](https://arxiv.org/abs/2509.19410)
*Chunhuan Zhang,Sean Cottrell,Benjamin Jones,Yueying Zhu,Huahai Qiu,Bengong Zhang,Tianshou Zhou,Jian Jiang*

Main category: q-bio.MN

TL;DR: 该研究提出了一种新颖的药物重定位方法，通过多尺度拓扑分析识别阿片成瘾关键基因，结合AI模型预测药物-靶点相互作用，最终筛选出具有治疗潜力的候选药物。


<details>
  <summary>Details</summary>
Motivation: 阿片危机迫切需要快速部署的治疗策略，本研究旨在弥合转录组数据分析与药物发现之间的差距，为阿片成瘾提供新的治疗选择。

Method: 对7个阿片成瘾转录组数据集进行差异基因表达分析，使用持久拉普拉斯算子进行多尺度拓扑分析识别关键基因，构建预测模型评估药物-靶点相互作用，并进行分子对接和ADMET评估。

Result: 识别出1,865个高置信度阿片成瘾相关靶点，通过交叉参考DrugBank编译重定位候选药物列表，并筛选出具有良好结合亲和力特征的化合物。

Conclusion: 该研究为阿片成瘾提供了可行的药物重定位策略，所提出的方法可推广应用于其他复杂疾病的药物开发。

Abstract: The ongoing opioid crisis highlights the urgent need for novel therapeutic
strategies that can be rapidly deployed. This study presents a novel approach
to identify potential repurposable drugs for the treatment of opioid addiction,
aiming to bridge the gap between transcriptomic data analysis and drug
discovery. Speciffcally, we perform a meta-analysis of seven transcriptomic
datasets related to opioid addiction by differential gene expression (DGE)
analysis, and propose a novel multiscale topological differentiation to
identify key genes from a protein-protein interaction (PPI) network derived
from DEGs. This method uses persistent Laplacians to accurately single out
important nodes within the PPI network through a multiscale manner to ensure
high reliability. Subsequent functional validation by pathway enrichment and
rigorous data curation yield 1,865 high-conffdence targets implicated in opioid
addiction, which are cross-referenced with DrugBank to compile a repurposing
candidate list. To evaluate drug-target interactions, we construct predictive
models utilizing two natural language processing-derived molecular embeddings
and a conventional molecular ffngerprint. Based on these models, we prioritize
compounds with favorable binding afffnity proffles, and select candidates that
are further assessed through molecular docking simulations to elucidate their
receptor-level interactions. Additionally, pharmacokinetic and toxicological
evaluations are performed via ADMET (absorption, distribution, metabolism,
excretion, and toxicity) proffling, providing a multidimensional assessment of
druggability and safety. This study offers a generalizable approach for drug
repurposing in other complex diseases beyond opioid addiction. Keywords: Opioid
addiction; Interactomic network; Topological perturbation; Differentially
expressed gene; Drug repurposin

</details>


<div id='stat.ML'></div>

# stat.ML [[Back]](#toc)

### [5] [BioBO: Biology-informed Bayesian Optimization for Perturbation Design](https://arxiv.org/abs/2509.19988)
*Yanke Li,Tianyu Cui,Tommaso Mansi,Mangal Prakash,Rui Liao*

Main category: stat.ML

TL;DR: BioBO是一种结合贝叶斯优化与生物先验知识的方法，用于高效设计基因组扰动实验，相比传统方法可提高25-40%的标注效率。


<details>
  <summary>Details</summary>
Motivation: 由于人类基因组的庞大搜索空间和实验限制，全面扰动基因组不可行。现有贝叶斯优化方法未能充分利用领域特定的生物先验知识。

Method: BioBO整合了贝叶斯优化、多模态基因嵌入和富集分析，将生物基础先验与采集函数结合，在保持探索不确定区域能力的同时偏向有前景的基因。

Result: 在公共基准测试和数据集上的实验表明，BioBO提高标注效率25-40%，比传统贝叶斯优化更有效地识别顶级扰动。

Conclusion: BioBO通过富集分析提供通路级解释，将设计选择与生物学一致的调控回路联系起来，提供机制可解释性。

Abstract: Efficient design of genomic perturbation experiments is crucial for
accelerating drug discovery and therapeutic target identification, yet
exhaustive perturbation of the human genome remains infeasible due to the vast
search space of potential genetic interactions and experimental constraints.
Bayesian optimization (BO) has emerged as a powerful framework for selecting
informative interventions, but existing approaches often fail to exploit
domain-specific biological prior knowledge. We propose Biology-Informed
Bayesian Optimization (BioBO), a method that integrates Bayesian optimization
with multimodal gene embeddings and enrichment analysis, a widely used tool for
gene prioritization in biology, to enhance surrogate modeling and acquisition
strategies. BioBO combines biologically grounded priors with acquisition
functions in a principled framework, which biases the search toward promising
genes while maintaining the ability to explore uncertain regions. Through
experiments on established public benchmarks and datasets, we demonstrate that
BioBO improves labeling efficiency by 25-40%, and consistently outperforms
conventional BO by identifying top-performing perturbations more effectively.
Moreover, by incorporating enrichment analysis, BioBO yields pathway-level
explanations for selected perturbations, offering mechanistic interpretability
that links designs to biologically coherent regulatory circuits.

</details>


<div id='cs.CV'></div>

# cs.CV [[Back]](#toc)

### [6] [A co-evolving agentic AI system for medical imaging analysis](https://arxiv.org/abs/2509.20279)
*Songhao Li,Jonathan Xu,Tiancheng Bao,Yuxuan Liu,Yuchen Liu,Yihang Liu,Lilin Wang,Wenhui Lei,Sheng Wang,Yinuo Xu,Yan Cui,Jialu Yao,Shunsuke Koga,Zhi Huang*

Main category: cs.CV

TL;DR: TissueLab是一个协同进化的智能AI系统，用于医学图像分析，通过集成多领域工具、支持实时交互和主动学习，在临床任务中达到最先进性能。


<details>
  <summary>Details</summary>
Motivation: 当前医学图像分析中智能AI的性能和应用受限，主要原因是缺乏健壮的生态系统、工具集不足以及缺少实时专家反馈。

Method: TissueLab整合病理学、放射学和空间组学领域的工具工厂，标准化工具输入输出，支持研究人员直接提问、自动生成可解释工作流程，并允许专家可视化中间结果和进行实时调整。系统通过主动学习持续从临床医生处学习。

Result: 在涉及分期、预后和治疗计划等临床意义的量化任务中，TissueLab相比端到端视觉语言模型和其他智能AI系统（如GPT-5）达到了最先进性能。系统能在几分钟内对未见过的疾病情境提供准确结果，无需大量数据集或长时间重新训练。

Conclusion: TissueLab作为一个可持续的开源生态系统发布，旨在加速医学影像的计算研究和转化应用，同时为下一代医学AI奠定基础。

Abstract: Agentic AI is rapidly advancing in healthcare and biomedical research.
However, in medical image analysis, their performance and adoption remain
limited due to the lack of a robust ecosystem, insufficient toolsets, and the
absence of real-time interactive expert feedback. Here we present "TissueLab",
a co-evolving agentic AI system that allows researchers to ask direct
questions, automatically plan and generate explainable workflows, and conduct
real-time analyses where experts can visualize intermediate results and refine
them. TissueLab integrates tool factories across pathology, radiology, and
spatial omics domains. By standardizing inputs, outputs, and capabilities of
diverse tools, the system determines when and how to invoke them to address
research and clinical questions. Across diverse tasks with clinically
meaningful quantifications that inform staging, prognosis, and treatment
planning, TissueLab achieves state-of-the-art performance compared with
end-to-end vision-language models (VLMs) and other agentic AI systems such as
GPT-5. Moreover, TissueLab continuously learns from clinicians, evolving toward
improved classifiers and more effective decision strategies. With active
learning, it delivers accurate results in unseen disease contexts within
minutes, without requiring massive datasets or prolonged retraining. Released
as a sustainable open-source ecosystem, TissueLab aims to accelerate
computational research and translational adoption in medical imaging while
establishing a foundation for the next generation of medical AI.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [7] [Nano Bio-Agents (NBA): Small Language Model Agents for Genomics](https://arxiv.org/abs/2509.19566)
*George Hong,Daniel Trejo Banos*

Main category: cs.AI

TL;DR: 该论文研究了使用小型语言模型（<100亿参数）通过智能体框架进行基因组学问答，以解决幻觉问题和计算成本挑战。提出的Nano Bio-Agent框架结合任务分解、工具编排和API访问，在GeneTuring基准测试中达到98%的准确率。


<details>
  <summary>Details</summary>
Motivation: 解决大型语言模型在基因组学应用中存在的幻觉问题和计算成本高昂的挑战，探索小型语言模型在保持高性能的同时降低资源需求的潜力。

Method: 开发了Nano Bio-Agent框架，将小型语言模型与任务分解、工具编排以及NCBI和AlphaGenome等系统API集成，通过智能体架构提升问答性能。

Result: 3-100亿参数的小型模型在GeneTuring基准测试中达到85-97%的准确率，最佳组合达到98%准确率，显著优于传统大型模型方法，同时计算资源需求大幅降低。

Conclusion: 小型语言模型结合智能体框架在基因组学问答中展现出巨大潜力，能够在保持高准确性的同时实现效率提升、成本节约和工具民主化。

Abstract: We investigate the application of Small Language Models (<10 billion
parameters) for genomics question answering via agentic framework to address
hallucination issues and computational cost challenges. The Nano Bio-Agent
(NBA) framework we implemented incorporates task decomposition, tool
orchestration, and API access into well-established systems such as NCBI and
AlphaGenome. Results show that SLMs combined with such agentic framework can
achieve comparable and in many cases superior performance versus existing
approaches utilising larger models, with our best model-agent combination
achieving 98% accuracy on the GeneTuring benchmark. Notably, small 3-10B
parameter models consistently achieve 85-97% accuracy while requiring much
lower computational resources than conventional approaches. This demonstrates
promising potential for efficiency gains, cost savings, and democratization of
ML-powered genomics tools while retaining highly robust and accurate
performance.

</details>


<div id='stat.ME'></div>

# stat.ME [[Back]](#toc)

### [8] [A decision-theoretic framework for uncertainty quantification in epidemiological modelling](https://arxiv.org/abs/2509.20013)
*Nicholas Steyn,Freddie Bickford Smith,Cathal Mills,Vik Shirvaikar,Christl A Donnelly,Kris V Parag*

Main category: stat.ME

TL;DR: 本文提出了一个基于决策理论的第一原理框架，将不确定性定义为基于不完整信息进行估计时产生的预期损失，为流行病学中的不确定性量化提供了更可靠、一致且与政策相关的基础。


<details>
  <summary>Details</summary>
Motivation: 流行病学中基于模型的估计经常影响现实世界决策，但不确定性来源很少被形式化，现有分类定义不一致，这阻碍了模型解释、比较和有目标的数据收集。

Method: 结合机器学习、信息理论、实验设计和健康经济学的思想，提出了一个决策理论框架，通过推理未来数据来定义可减少和不可减少的不确定性概念。

Result: 通过新西兰SARS-CoV-2废水监测的案例研究，展示了该框架的应用，估计了如果将废水监测扩展到全人口时的不确定性减少程度。

Conclusion: 该框架统一并扩展了相关领域的思想，为传染病流行病学提供了更可靠、一致和与政策相关的不确定性量化基础。

Abstract: Estimating, understanding, and communicating uncertainty is fundamental to
statistical epidemiology, where model-based estimates regularly inform
real-world decisions. However, sources of uncertainty are rarely formalised,
and existing classifications are often defined inconsistently. This lack of
structure hampers interpretation, model comparison, and targeted data
collection. Connecting ideas from machine learning, information theory,
experimental design, and health economics, we present a first-principles
decision-theoretic framework that defines uncertainty as the expected loss
incurred by making an estimate based on incomplete information, arguing that
this is a highly useful and practically relevant definition for epidemiology.
We show how reasoning about future data leads to a notion of expected
uncertainty reduction, which induces formal definitions of reducible and
irreducible uncertainty. We demonstrate our approach using a case study of
SARS-CoV-2 wastewater surveillance in Aotearoa New Zealand, estimating the
uncertainty reduction if wastewater surveillance were expanded to the full
population. We then connect our framework to relevant literature from adjacent
fields, showing how it unifies and extends many of these ideas and how it
allows these ideas to be applied to a wider range of models. Altogether, our
framework provides a foundation for more reliable, consistent, and
policy-relevant uncertainty quantification in infectious disease epidemiology.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [9] [PGCLODA: Prompt-Guided Graph Contrastive Learning for Oligopeptide-Infectious Disease Association Prediction](https://arxiv.org/abs/2509.20290)
*Dayu Tan,Jing Chen,Xiaoping Zhou,Yansen Su,Chunhou Zheng*

Main category: cs.LG

TL;DR: 本文提出了PGCLODA框架，一种基于提示引导图对比学习的方法，用于预测寡肽与传染病之间的关联，在多个指标上优于现有最先进模型。


<details>
  <summary>Details</summary>
Motivation: 传染病对公共卫生构成严重威胁，寡肽因其结构简单、生物利用度高和耐药性低而成为有前景的抗感染候选药物，但专门用于预测寡肽与传染病关联的计算模型仍然稀缺。

Method: 构建包含寡肽、微生物和疾病的三方图，采用提示引导的图增强策略生成有意义的对比视图，使用GCN和Transformer双编码器架构捕获局部和全局特征，最后通过MLP分类器进行预测。

Result: 在基准数据集上的实验结果表明，PGCLODA在AUROC、AUPRC和准确率方面持续优于最先进模型，消融实验和超参数研究验证了各模块的贡献。

Conclusion: PGCLODA具有良好的泛化能力，能够发现具有生物学意义的新关联，为机制驱动的发现和基于寡肽的药物开发提供了有价值的见解。

Abstract: Infectious diseases continue to pose a serious threat to public health,
underscoring the urgent need for effective computational approaches to screen
novel anti-infective agents. Oligopeptides have emerged as promising candidates
in antimicrobial research due to their structural simplicity, high
bioavailability, and low susceptibility to resistance. Despite their potential,
computational models specifically designed to predict associations between
oligopeptides and infectious diseases remain scarce. This study introduces a
prompt-guided graph-based contrastive learning framework (PGCLODA) to uncover
potential associations. A tripartite graph is constructed with oligopeptides,
microbes, and diseases as nodes, incorporating both structural and semantic
information. To preserve critical regions during contrastive learning, a
prompt-guided graph augmentation strategy is employed to generate meaningful
paired views. A dual encoder architecture, integrating Graph Convolutional
Network (GCN) and Transformer, is used to jointly capture local and global
features. The fused embeddings are subsequently input into a multilayer
perceptron (MLP) classifier for final prediction. Experimental results on a
benchmark dataset indicate that PGCLODA consistently outperforms
state-of-the-art models in AUROC, AUPRC, and accuracy. Ablation and
hyperparameter studies confirm the contribution of each module. Case studies
further validate the generalization ability of PGCLODA and its potential to
uncover novel, biologically relevant associations. These findings offer
valuable insights for mechanism-driven discovery and oligopeptide-based drug
development. The source code of PGCLODA is available online at
https://github.com/jjnlcode/PGCLODA.

</details>
